Disappearance of Factor V Activity after Incubation of Plasma with Heparin and Heparinoids

R Holemans; C Vermylen; M Verstraete

doi:10.1055/s-0038-1654512

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1960; 4(03): 303-322
DOI: 10.1055/s-0038-1654512

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

Disappearance of Factor V Activity after Incubation of Plasma with Heparin and Heparinoids^[*]

Authors

R Holemans

¹Laboratory of Physiopathology of the Department of Medicine (Prof. J. Vandenbroucke), University of Louvain, Belgium
C Vermylen

¹Laboratory of Physiopathology of the Department of Medicine (Prof. J. Vandenbroucke), University of Louvain, Belgium
M Verstraete^**

¹Laboratory of Physiopathology of the Department of Medicine (Prof. J. Vandenbroucke), University of Louvain, Belgium

Abstract

Summary

1. Heparin and heparinoids, added to oxalated or citrated plasma produce in this plasma an inactivation of factor V; this inactivation is progressive and directly related to the length of incubation.

The rate of inactivation of factor V is directly proportional to the quantity of anticoagulant added.

2. When quantities with identical anticoagulant activity in the thromboplastin-calcium clotting time are compared, heparin proves to have a stronger effect than heparinoids.

3. The inactvation of factor V in plasma by heparin or heparinoïds is an irreversible process, which cannot be nullified by addition of protamine sulphate.

Full Text

References

References
(1) Howell W. H, Holt E. Two new factors in blood coagulation: heparin and proantithrombin. Amer. J. Physiol. 47: 328-341 1918;
(2) Nilsson L, Wenckert A. Demonstration of a Heparin-like Anticoagulant in Normal Blood. Acta med. scand. Suppl. 297 1954;
(3) Wenckert A, Nilsson I. M. Thromboplastin and Russell Viper Venom. Investigation on the activation of Prothrombin. Scand. J. clin. Lab. Invest. 7 Suppl. 15 1955;
(4) Dyckerhoff H, Miehler H, Steiner R. Über die Gerinnung des Blutes. Thrombin. Biochem. Z. 297: 342-346 1938;
(5) Schullze H. E, Schwieck G. Über den Mechanismus der Thrombinbildung im isolierten System. Hoppe-Seyler’s Z. Physiol. Chem. 289: 26-43 1951;
(6) Laki K. Chemistry of Prothrombin and some of its reactions. Physiol. Reviews 34: 730-735 1954;
(7) Brinkhous K. M, Smith H. P, Warner E. D, Seegers W. H. The inhibition of blood clotting: an unidentifed substance which acts in conjunction with heparin to prevent the conversion of prothrombin to thrombin. Amer. J. Physiol. 125: 683-687 1939;
(8) Marbet R, Winterstein A. Über die Wirkung von Antikoagulantien des Heparintypus auf die 1. Phase der Blutgerinnung. Helv. physiol, pharmacol. Acta 10: 528-542 1952;
(9) Winterstein A. Symposium sur les Macromolécules: Héparine et Héparinoïdes. Centenaire de l’Institut National Genevois; Volume hors-série 93-109 1954
(10) Brambell C. E, Corwin A. H, Capone V. A. Mechanism of the Action of Heparin as an etiological Basis for Homeostatis (Hemorrhage and Thrombosis). Amer. J. med. Sci. 230: 276 1955;
(11) Beaumont J. L, Beaumont V. Le sulphate de dextrane. Son action anticoagulante clinique étiologique. Le Sang 28: 61-77 1957;
(12) Michaelis J. Diethylobarbiturate Buffer. J. biol. Chem. 87: 33 1930;
(13) Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VII). Acta haemat. 6: 1-18 1951;
(14) Wolf P. A modification for Routine Laboratory Use of Stefanini's Method of estimating Factor V in human oxalated Plasma. J. clin. Path. 6: 34-38 1953;
(15) Holemans R, Vermylen C, Verstraete M. Antithrombin Activity of Heparin and Heparinoïds. Is prepared.
(16) Holemans R, Verstraete M. Influence of heparin and heparinoïds on thromboplastin formation. Is prepared.
(17) Douglas A. S. The action of Heparin in the Prevention of Prothrombin Conversion. J. clin. Invest. 35: 533 1956;
(18) Nieth H, Mammen E, Gross R. Zur Heparinisierung des Blutes bei der extrakorporealen Hämodialyse. Klin. Wschr. 36: 372-376 1958;
(19) Hougie C, Garrard M. E, Warren W. D, Dammann F, Muller W. H. Coagulation Problems Relating to the Use of the Extracorporeal Circulation in Man. Proceedings of the 7th Congress of the International Society of Blood Transfusion. Rome: 1958: 28 Edit. by Karger S. 1959.
(20) Spohn K, Kolb E, Heinzel J, Kratzert R, Wenz W, Woerner W, Lasch H. G, Sessner H. H, Raule W, Gottstein U, Kuhn E, Schreiner K. 30. Ergebnisse von Tierversuchen mit der Herz-Lungen-Maschine nach Crafoord-Senning. Langenbecks Archiv und Dtsch. Z. Chir. 289: 705-713 1958;
(21) Holemans R, Verstraete M, Joossens J. V. Clotting Deviations during complete cardiac Bypass. Is prepared.
(22) Verwilghen R. Verbruik van Prothrombine en Acceleratoren. Proefschrift Wedstrijd Reisbeurzen van de Belgische Staat; 1953

Disappearance of Factor V Activity after Incubation of Plasma with Heparin and Heparinoids[*]

Authors

Disappearance of Factor V Activity after Incubation of Plasma with Heparin and Heparinoids^[*]